Inflammatory bowel diseases are chronic inflammatory diseases of the gastrointestinal tract characterised by recurring inflammations of particular segments of the gastrointestinal tract, the clinical manifestation of which include bloatedness, abdominal pains, cramps, bleeping and chronic diarrhea. Two diseases belong to this group: Crohn's disease and ulcerative colitis. Despite safe and effective pharmacological treatment options, which include aminosalicylates, corticosteroids, immunosuppressives and biological therapy, many patients suffering from these complex diseases are seeking solutions to their medical issues in food supplements. Some of these food supplements may pose public health risks due to the presence of residual solvents in them not being properly reported. Residual solvents are volatile organic chemical substances that may have been used or produced in the preparation of a medicinal product. They are classified from Class 1 to Class 3 based on their potential dangers to human health. In order to determine the presence of residual solvents in food supplements used for the treatment of inflammatory bowel disease, method <467> defined by the United States Pharmacopeia was used. Multiple samples from the Croatian market were prepared and analysed using HSS-GC-FID and then compared with chromatograms of analysed standards containing Class 2 and Class 3 residual solvents. Using this method, the presence of residual solvents was determined in 21 out of 44 analysed samples, with all of the detected residual solvents being within acceptable limits, making them safe for human use.